Great West Life Assurance Co. Can increased its position in shares of GRIFOLS S A/S (NASDAQ:GRFS) by 16.2% in the 3rd quarter, HoldingsChannel reports. The fund owned 540,365 shares of the biotechnology company’s stock after buying an additional 75,418 shares during the quarter. Great West Life Assurance Co. Can’s holdings in GRIFOLS S A/S were worth $11,591,000 as of its most recent SEC filing.
Several other large investors have also recently made changes to their positions in the stock. Verition Fund Management LLC raised its holdings in GRIFOLS S A/S by 23.2% during the second quarter. Verition Fund Management LLC now owns 18,818 shares of the biotechnology company’s stock valued at $405,000 after buying an additional 3,539 shares in the last quarter. AMP Capital Investors Ltd bought a new position in GRIFOLS S A/S during the second quarter valued at about $438,000. Janney Montgomery Scott LLC bought a new position in GRIFOLS S A/S during the third quarter valued at about $438,000. Moody National Bank Trust Division bought a new position in GRIFOLS S A/S during the third quarter valued at about $463,000. Finally, Dynamic Technology Lab Private Ltd raised its holdings in GRIFOLS S A/S by 92.5% during the second quarter. Dynamic Technology Lab Private Ltd now owns 25,951 shares of the biotechnology company’s stock valued at $558,000 after buying an additional 12,470 shares in the last quarter. Institutional investors and hedge funds own 20.17% of the company’s stock.
GRIFOLS S A/S stock opened at $19.51 on Friday. The company has a debt-to-equity ratio of 1.47, a quick ratio of 1.07 and a current ratio of 2.78. The stock has a market capitalization of $13.20 billion, a PE ratio of 17.74, a price-to-earnings-growth ratio of 1.39 and a beta of 1.12. GRIFOLS S A/S has a 52 week low of $17.47 and a 52 week high of $25.18.
Several equities analysts have weighed in on the company. Zacks Investment Research upgraded GRIFOLS S A/S from a “sell” rating to a “hold” rating in a report on Tuesday, November 13th. BidaskClub lowered GRIFOLS S A/S from a “hold” rating to a “sell” rating in a report on Wednesday, October 17th. UBS Group lowered GRIFOLS S A/S from a “neutral” rating to a “sell” rating in a report on Wednesday, October 3rd. Santander upgraded GRIFOLS S A/S from an “underperform” rating to a “hold” rating in a report on Tuesday, October 30th. Finally, Berenberg Bank upgraded GRIFOLS S A/S from a “hold” rating to a “buy” rating in a research note on Thursday, October 11th. Three research analysts have rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company’s stock. GRIFOLS S A/S presently has an average rating of “Hold” and an average target price of $21.50.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.chaffeybreeze.com/2018/12/07/great-west-life-assurance-co-can-purchases-75418-shares-of-grifols-s-a-s-grfs.html.
GRIFOLS S A/S Company Profile
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others.
Featured Article: Why investors pay attention to retained earnings
Want to see what other hedge funds are holding GRFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GRIFOLS S A/S (NASDAQ:GRFS).
Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.